Loading
A phase 2 trial of H101 oncolytic adenovirus in Head and neck squamous cell carcinoma, run by West China Hospital, now recruiting.
H101 Plus TACE for r/m HNSCC is a phase 2 interventional study registered as NCT07398664 by West China Hospital, with 20 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-06-15. Interventions recorded: H101, TACE. Conditions recorded: Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE.
Linked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares H101 oncolytic adenovirus and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.